Cancer treatment-related neuropathic pain: proof of concept study with menthol—a TRPM8 agonist

M. T. Fallon (Lead / Corresponding author), D. J. Storey, A. Krishan, C. J. Weir, R. Mitchell, S. M. Fleetwood-Walker, A. C. Scott, L. A. Colvin

Research output: Contribution to journalArticlepeer-review

46 Citations (Scopus)
136 Downloads (Pure)

Abstract

Purpose: Effective treatment of neuropathic pain without unacceptable side effects is challenging. Cancer sufferers increasingly live with long-term treatment-related neuropathic pain, resulting from chemotherapy-induced peripheral neuropathy (CIPN) or surgical scars. This proof-of-concept study aimed to determine whether preclinical evidence for TRPM8 ion channels in sensory neurons as a novel analgesic target could be translated to clinical benefit in patients with neuropathic pain, using the TRPM8 activator menthol.

Patients and methods: Patients with problematic treatment-related neuropathic pain underwent a baseline assessment using validated questionnaires, psychophysical testing, and objective functional measures. The painful area was treated with topical 1 % menthol cream twice daily. Assessments were repeated at 4–6 weeks. The primary outcome was the change in Brief Pain Inventory total scores at 4–6 weeks. Secondary outcomes included changes in function, mood and skin sensation.

Results: Fifty-one patients (female/male, 32/19) were recruited with a median age of 61 (ranging from 20 to 89). The commonest aetiology was CIPN (35/51), followed by scar pain (10/51). Thirty-eight were evaluable on the primary outcome. Eighty-two per cent (31/38) had an improvement in total Brief Pain Inventory scores (median, 47 (interquartile range, 30 to 64) to 34 (6 to 59), P < 0.001). Improvements in mood (P = 0.0004), catastrophising (P = 0.001), walking ability (P = 0.008) and sensation (P < 0.01) were also observed.

Conclusion: This proof-of-concept study indicates that topical menthol has potential as a novel analgesic therapy for cancer treatment-related neuropathic pain. Improvements in patient-rated measures are supported by changes in objective measures of physical function and sensation. Further systematic evaluation of efficacy is required.
Original languageEnglish
Pages (from-to)2769-2777
Number of pages9
JournalSupportive Care in Cancer
Volume23
Issue number9
Early online date15 Feb 2015
DOIs
Publication statusPublished - Sep 2015

Keywords

  • Menthol
  • TRPM8
  • Neuropathic
  • Pain
  • Cancer
  • Chemotherapy

Fingerprint Dive into the research topics of 'Cancer treatment-related neuropathic pain: proof of concept study with menthol—a TRPM8 agonist'. Together they form a unique fingerprint.

Cite this